The conditional promise of dual-epitope HER2 antibody-drug conjugates in breast cancer
摘要
In the landscape of neoadjuvant therapy for breast cancer,achieving a pathologic complete response(pCR)to improve long-term survival remains the paramount clinical objective1.Although traditional dual human epidermal growth factor receptor 2(HER2)-targeted therapies combined with chemo-therapy have improved pCR rates in HER2-positive breast cancer2,their associated systemic toxicities and current effi-cacy plateaus have compelled researchers to seek more precise alternative strategies.
年,卷(期):
2026, 23(9)
机标分类号:
G2
在线出版日期:
2026年10月13日